Alto Neuroscience (ANRO) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Latigo Biotherapeutics is the larger company by market cap ($975.6 million vs $941.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | LTGO |
|---|---|---|
| Share price | $23.98 | $14.72 |
| Market cap | $941.03M | $975.59M |
| 1-day change | +1.96% | -5.16% |
| YTD return | +32.13% | — |
| 1-year return | +295.96% | — |
| EPS (TTM) | $-2.31 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.48 | $25.93 |
| 52-week low | $5.23 | $14.60 |
| Distance from 52-week high | -36.02% | -43.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +60.05% | +255.08% |
| Average volume | 540.09K | 394.20K |
| Shares outstanding | 39.24M | 66.30M |
| Employees | 68 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
ANRO vs LTGO FAQ
Which is bigger, Alto Neuroscience or Latigo Biotherapeutics?
Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $975.59M compared with $941.03M for Alto Neuroscience (ANRO).
Are Alto Neuroscience and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.